Latest news with #ClinicalTrials.gov


Techday NZ
7 days ago
- Health
- Techday NZ
Elsevier unveils Embase AI to transform biomedical data research
Elsevier has launched Embase AI, a generative artificial intelligence tool aimed at changing how researchers and medical professionals access and analyse biomedical data. The tool has been developed in collaboration with the scientific community and is built upon Elsevier's Embase platform, a widely used biomedical literature database. According to feedback from beta users, Embase AI can reduce the time spent on reviewing biomedical data by as much as 50%. Natural language features Among its central features, Embase AI allows users to conduct searches in natural language, ranging from basic to complex scientific queries. The system then provides instant summaries of the relevant data and research insights. Each answer comes with a list of linked citations to assist users in evaluating the evidence and meeting expectations around medical regulation. Unlike some other AI solutions that may obscure data provenance, Embase AI delivers transparency by presenting citations and ensuring that the underlying sources can be cross-checked. The database underpinning Embase AI is updated continuously and includes records such as adverse drug reaction reports, peer-reviewed journal articles, and around 500,000 clinical trial listings from This makes it suitable for a range of professional needs, including medical research, pharmacovigilance, regulatory submissions and the generation of market insights. Expanded access By enabling natural language querying, Embase AI seeks to open up biomedical data analysis to a broader group of users, including those who may lack advanced technical experience with literature reviews. Information is summarised for swift consumption while retaining the supporting references, limiting the likelihood that important findings go overlooked. The AI solution uses a dual-stage ranking system to generate summary responses with inline citations. This approach is designed to ensure transparency and help users trust the results. A human-curated hierarchy of medical concepts and their synonyms underpins the system, contributing to the precision and transparency of its outputs. Embase AI's records are updated daily, and its architecture allows the tool to function in real time, searching the platform's full content including peer-reviewed research, clinical trials, preprints and conference abstracts. Security and privacy Elsevier has stated that Embase AI was developed in accordance with its Responsible AI Principles and Privacy Principles to ensure robust data privacy and security. The company notes that the model's use of third-party large language models (LLMs) is private, with no user information being stored or employed to train public versions of these models. All data is retained solely within Elsevier's protected environment. "Embase AI is changing the way researchers and other users go about solving problems and helps them save valuable time searching for answers, digesting information, and avoiding the risk of missing valuable insights. Every user should have access to trusted research tools that help them advance human progress, and we remain committed to working in partnership with scientists across academia, life sciences and other innovative industries to ensure that our solutions address their needs. We know that our users seek solutions that they can trust, and we built Embase AI in a way that ensures transparency, explainability and accuracy." This statement was made by Mirit Eldor, Managing Director, Life Sciences at Elsevier. Ongoing development Embase AI is the latest addition to Elsevier's suite of products aimed at supporting the biomedical research community by facilitating discovery, analysis, and evidence synthesis using responsibly developed AI tools underpinned by trusted content. The platform is designed to meet the needs of professionals in roles such as research and development, medical affairs, academic research, knowledge management, and medical education.


Tokyo Reported
25-06-2025
- Health
- Tokyo Reported
Experimental Treatments Continue To Gain Popularity
The landscape of medical treatment is rapidly evolving as experimental therapies gain unprecedented traction among patients, healthcare providers, and regulatory bodies worldwide. This surge in interest reflects both advancing scientific capabilities and growing patient demand for access to cutting-edge treatments that may offer hope where traditional therapies have fallen short. Rising Numbers in Clinical Trial Participation According to GlobalData's Pharmaceutical Intelligence Centre, most trials completed in 2024 were Phase I studies (40.92%), with the second highest completion in Phase II (36.28%). During 2024, 15.62% of trial completions were Phase III studies. In 2024, there were 7,089 completions, demonstrating the robust pipeline of experimental treatments moving through the research and development process. currently lists 455,437 studies with locations in all 50 States and in 221 countries. As of March 2021, receives about 4.5 million visitors monthly, indicating substantial public interest in experimental treatment options. This massive database represents one of the most comprehensive resources for patients seeking information about ongoing clinical trials and experimental therapies. The global reach of experimental treatments has expanded significantly, with most (75%) included both males and females in trial designs, while most (73%) included adults in their inclusion criteria while 12% included children. This broad inclusivity demonstrates the medical community's commitment to developing treatments that can benefit diverse patient populations. Cancer Treatment Leading the Experimental Frontier Cancer research continues to dominate the experimental treatment landscape, with remarkable success rates emerging from recent clinical trials. Patients with cancer commonly participate in many kinds of clinical studies, including 7% in treatment trials, representing hundreds of thousands of individuals who are actively participating in the development of tomorrow's standard treatments. The results from these experimental cancer therapies have been particularly encouraging. Some recent trials have shown success rates exceeding 70 percent in certain patient populations, demonstrating the potential of these innovative approaches to transform cancer care. These promising outcomes have contributed significantly to the growing enthusiasm for experimental treatments among both patients and oncologists. Regulatory Changes and Access Expansion The regulatory environment surrounding experimental treatments has undergone significant changes to accommodate growing demand and evolving scientific understanding. Montana just passed a new bill backed by longevity enthusiasts that will enable access to drugs and therapies that are not approved by the FDA, representing a notable shift in how states are approaching experimental treatment access. This regulatory evolution reflects broader trends in healthcare policy that prioritize patient autonomy and expanded access to potentially life-saving treatments. The movement toward more flexible regulatory frameworks has been driven by patient advocacy groups, healthcare providers, and researchers who argue that traditional approval timelines may be too restrictive for patients facing serious medical conditions. Post Trial Access Challenges and Solutions One of the most significant developments in experimental treatment policy involves post-trial access for patients who have participated in clinical studies. Post-Trial, Continued Access can be defined as the continued provision of the investigational medicine or continued maintenance of the investigational significant risk device for any clinical trial participant after participation in the trial. This concept has become increasingly important as more patients participate in experimental treatments and require ongoing access to therapies that may not yet be commercially available. Post-trial, continued access is a shared responsibility and should be determined before the trial begins, highlighting the need for comprehensive planning and coordination among sponsors, researchers, healthcare systems, and regulatory bodies. This approach ensures that patients who have contributed to medical research by participating in experimental treatments are not left without access to potentially beneficial therapies once formal trials conclude. The implementation of post-trial access for patients has required careful consideration of ethical, financial, and logistical factors. Healthcare systems must balance the need to provide continued treatment access with resource limitations and regulatory requirements. This has led to the development of innovative funding mechanisms and partnership arrangements between pharmaceutical companies, healthcare providers, and government agencies. Technology and Digital Health Integration The experimental treatment landscape has been significantly enhanced by technological advances and digital health integration. Since May 2021, at least 94 PDTs gained new approvals and/or market access globally, including 51 in Germany alone, demonstrating the rapid adoption of digital therapeutics as experimental treatment options. These digital health solutions represent a new frontier in experimental treatments, offering patients access to innovative therapies that can be delivered remotely and monitored in real-time. The integration of artificial intelligence, machine learning, and advanced data analytics has enabled researchers to develop more personalized experimental treatments and improve patient outcomes. Economic Impact and Market Growth The economic implications of the growing experimental treatment sector are substantial. Breakthrough therapies launched over the past decade for multiple diseases are re-shaping patient care in many areas and the outlook for medicines use – and the related Spending – through 2028 is higher than prior forecasts as more novel drugs become available. This economic growth reflects not only increased investment in research and development but also growing patient willingness to pursue experimental treatment options. The expansion of insurance coverage for experimental treatments and the development of patient assistance programs have made these therapies more accessible to broader patient populations. Future Outlook and Implications The continued growth in experimental treatment popularity represents a fundamental shift in healthcare delivery and patient expectations. About 80% of clinical trials experience delays or are prematurely terminated due to challenges in recruiting participants, yet increasing patient interest in experimental treatments may help address these recruitment challenges and accelerate the development of new therapies. As experimental treatments continue to gain popularity, healthcare systems must adapt to support increased demand while maintaining safety standards and ethical oversight. The success of these efforts will ultimately determine how quickly promising experimental treatments can be translated into standard care options that benefit patients worldwide. The trend toward experimental treatment adoption reflects broader changes in healthcare, including increased patient engagement, technological advancement, and evolving regulatory frameworks. These developments suggest that experimental treatments will continue to play an increasingly important role in modern medicine, offering hope and healing options to patients facing complex medical challenges.
Yahoo
18-06-2025
- Health
- Yahoo
Canomiks Launches WhatToTrust™, First Science-Based Platform to Help Consumers Make Confident Dietary Supplement Choices
ROCHESTER, Minn., June 18, 2025 /PRNewswire/ -- With the rising popularity of dietary supplements and functional health products, consumers face an increasingly complex and confusing market. Overwhelmed by bold health claims, influencer endorsements, and limited access to reliable product quality and scientific data, many struggle to identify trustworthy products. To address this challenge, Canomiks is proud to announce the launch of WhatToTrust™, a no-cost, user-friendly platform providing unbiased, science-based evaluations of wellness products through a transparent proprietary product scoring system. WhatToTrust™ features a comprehensive database of hundreds of products, including botanicals, vitamins, probiotics, protein powders, and supplements targeting specific health concerns like menopause, stress, immune health, and sports nutrition. Each product receives a WhatToTrust™ Score from 1 to 10 (10 being the best), based on a rigorous evaluation of scientific information available on the product brand's website. This includes references to FDA required tests for ingredient identity, potency, and purity, as well as scientific research such as pre-clinical and human clinical trials. Data is also sourced from reputable scientific and clinical databases like and Products are assessed not only at the whole formulation level but also at the individual ingredient level to ensure product quality and scientific validation. Features such as 'Compare Products' allow consumers to compare WhatToTrust™ scores and ingredients. Canomiks does not charge product companies any listing fees, ensuring unbiased scores. If Canomiks performs independent testing on a product, it is clearly noted in the score breakdown. By providing transparent, simplified, and reliable insights alongside WhatToTrust™ product scores, the platform empowers consumers to make informed and confident health and wellness choices. Terms like "science-backed," "doctor-approved," and "clinically proven" are frequently used in supplement marketing, but these claims are not always supported by robust scientific research. WhatToTrust™ introduces crucial transparency to the market, enabling consumers to verify product claims against credible scientific evidence and publicly available research. With some studies estimating that 75% of American adults take dietary supplements, the need for trustworthy, science-based information is paramount. WhatToTrust™ meets this demand by offering an accessible platform for consumers to assess product efficacy based on the strength of the presented scientific evidence. "Consumers deserve access to unbiased, evidence-based information when choosing wellness products," said Dr. Leena Pradhan-Nabzdyk, Founder of Canomiks. "While the supplement industry is regulated, it's not to the same standard as drugs and devices. Regulatory compliance alone doesn't guarantee efficacy studies, which are rooted in science. Our WhatToTrust™ scoring system goes beyond regulatory requirements to incorporate preclinical and clinical research evidence, ensuring products are backed by solid science." "Product ratings based upon clinical evidence counters the misinformation consumers sometimes hear that nutraceuticals are unregulated, untested, and unsafe," said Elan Sudberg, CEO of Alkemist Labs, a top botanical testing lab. "WhatToTrust™ is a centralized, easy-to-navigate resource empowering consumers to make smarter decisions by revealing the science behind their chosen products. It also provides healthcare providers with a reliable tool to confidently recommend trustworthy supplement options," added Dr. Leena Pradhan-Nabzdyk. Visit to learn more. Canomiks is a life sciences company leading the future of the functional food, beverage, and dietary supplement industries through innovative genomics, bioinformatics, and AI-based solutions. Their technology innovates new formulations and validates the biological efficacy and safety of functional ingredients and products. Founded by three esteemed Harvard scientists, Canomiks utilizes exclusive intellectual property to bring unparalleled truth, transparency, and trust to the natural products market. The company's vision, "Make Food as Medicine a Reality®," drives its mission to improve community health and sustainability. For more information, visit Contact:Liz BeckmannMarketing and Operations Managerliz@ View original content to download multimedia: SOURCE Canomiks, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
16-06-2025
- Health
- Business Wire
Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2A Study Evaluating CMTX-101 for Infections Associated With Cystic Fibrosis
COLUMBUS, Ohio--(BUSINESS WIRE)-- Clarametyx Biosciences, Inc. ('Clarametyx'), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases, announced today that it is advancing a Phase 1b/2a clinical trial evaluating its novel immune-enabling antibody therapy CMTX-101 to treat cystic fibrosis (CF)-associated pulmonary infections, based on the DMC's approval to proceed following results of a pre-specified interim analysis. 'Interim findings from this study have identified encouraging trends that support the potential benefit of CMTX-101, with no safety issues,' said Jerry Nick, MD, Professor in the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health, and primary investigator of the study. 'The next portion of the trial will provide important insights on the potential therapeutic impact of CMTX-101 for the CF population as a novel solution to reduce the burden of chronic infections.' The ongoing randomized, double-blind, placebo-controlled clinical trial is assessing CMTX-101 as an adjunctive therapy to standard of care antibiotics in people with CF, evaluating safety and tolerability, pharmacokinetics, immunogenicity, reduction of pulmonary Pseudomonas aeruginosa burden, and additional exploratory endpoints. An interim analysis of data from the first 21 participants enrolled met the pre-specified criteria to continue the trial at both 5 and 30 mg/kg dose levels. Participants treated with CMTX-101 demonstrated a reduction in P. aeruginosa burden based on prespecified statistical criteria and CMTX-101 was shown to be present in the sputum of all treated participants. Importantly, CMTX-101 was generally well tolerated, consistent with the findings reported in a prior clinical study, and no antidrug antibodies were detected. The upcoming portion of the study will continue evaluating both doses of CMTX-101 versus placebo among approximately 20 additional participants from 23 study sites, including significant support from the Cystic Fibrosis Therapeutics Development Network. Study enrollment is expected to be complete by the end of 2025. More information on the study and participating sites is available at ( using the identifier NCT06159725. 'We are pleased that the findings from the first 21 participants enrolled support progressing the study without modification. The full dataset, which will include exploratory endpoints such as respiratory function, inflammatory biomarkers and quality of life assessments, will help us further understand the full potential of CMTX-101 as a novel therapeutic solution to a variety of chronic respiratory conditions,' said David V. Richards, Chief Executive Officer, Clarametyx. 'We extend our gratitude to the Cystic Fibrosis Therapeutics Development Network, clinical investigators, and the participants and families for their continued participation in this important research.' About CMTX-101 CMTX-101 is an investigational immune-enabling antibody therapy in development to treat chronic and recalcitrant respiratory infections. The therapy is designed to precisely and rapidly destroy the universal underlying structure of bacterial biofilms to undermine extracellular bacterial defenses and enable more effective antibiotic and immune intervention. Because the target is universally present across bacteria, the approach can be employed to treat a range of bacterial infections and pathogen types. The goal of treatment is to dramatically improve the effectiveness of antibiotic therapies and innate immune system effectors, improving the time to resolution of the infection and reducing the need for repeated courses of antibiotics. It is currently in development to treat cystic fibrosis-associated infections, with opportunities to expand to other chronic respiratory infections including nontuberculous mycobacterial (NTM) lung disease, non-CF bronchiectasis (NCFB), and chronic obstructive pulmonary disease (COPD). About Clarametyx Biosciences Clarametyx Biosciences is combating the formidable challenge of chronic, recalcitrant respiratory infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2 study for infections associated with cystic fibrosis, and CMTX-301, which is in early development. For more information, visit us on the web or on LinkedIn.


Business Upturn
06-06-2025
- Business
- Business Upturn
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
By GlobeNewswire Published on June 6, 2025, 23:41 IST Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) — First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.